Cargando…

Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHANG, JIAN, ZHANG, WEIQING, HUANG, SHAOHONG, LI, HUI, LI, YUN, CHEN, HUIGUO, WU, WEIBING, ZHOU, WEI, WANG, CUIPING, LIAO, HONGYING, GU, LIJIA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493745/
https://www.ncbi.nlm.nih.gov/pubmed/23226738
http://dx.doi.org/10.3892/etm.2012.690
_version_ 1782249318295535616
author ZHANG, JIAN
ZHANG, WEIQING
HUANG, SHAOHONG
LI, HUI
LI, YUN
CHEN, HUIGUO
WU, WEIBING
ZHOU, WEI
WANG, CUIPING
LIAO, HONGYING
GU, LIJIA
author_facet ZHANG, JIAN
ZHANG, WEIQING
HUANG, SHAOHONG
LI, HUI
LI, YUN
CHEN, HUIGUO
WU, WEIBING
ZHOU, WEI
WANG, CUIPING
LIAO, HONGYING
GU, LIJIA
author_sort ZHANG, JIAN
collection PubMed
description The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. The meta-analysis was performed using Reviewer Manager Version 5.12 software. Compared with the control group, maintenance erlotinib improved progression-free survival (PFS) and overall survival (OS) with moderate heterogeneity. Results from the random effects model analysis for OS were not in concordance with the difference observed in the fixed effects model analysis. Administration of erlotinib only after chemotherapy obtained a higher objective response rate (ORR). Safety analyses indicated a slight increase in side-effects. The most common adverse events (AEs) were diarrhea and rash, which were usually manageable. There was no significant difference in treatment-related deaths. Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. However, more well-designed randomized control trials (RCTs) are required to identify patients that may derive greater benefits from maintenance with erlotinib, and whether the use of erlotinib as maintenance therapy is more efficient than second-line treatment should also be investigated.
format Online
Article
Text
id pubmed-3493745
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-34937452012-12-06 Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials ZHANG, JIAN ZHANG, WEIQING HUANG, SHAOHONG LI, HUI LI, YUN CHEN, HUIGUO WU, WEIBING ZHOU, WEI WANG, CUIPING LIAO, HONGYING GU, LIJIA Exp Ther Med Articles The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. The meta-analysis was performed using Reviewer Manager Version 5.12 software. Compared with the control group, maintenance erlotinib improved progression-free survival (PFS) and overall survival (OS) with moderate heterogeneity. Results from the random effects model analysis for OS were not in concordance with the difference observed in the fixed effects model analysis. Administration of erlotinib only after chemotherapy obtained a higher objective response rate (ORR). Safety analyses indicated a slight increase in side-effects. The most common adverse events (AEs) were diarrhea and rash, which were usually manageable. There was no significant difference in treatment-related deaths. Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. However, more well-designed randomized control trials (RCTs) are required to identify patients that may derive greater benefits from maintenance with erlotinib, and whether the use of erlotinib as maintenance therapy is more efficient than second-line treatment should also be investigated. D.A. Spandidos 2012-11 2012-08-31 /pmc/articles/PMC3493745/ /pubmed/23226738 http://dx.doi.org/10.3892/etm.2012.690 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
ZHANG, JIAN
ZHANG, WEIQING
HUANG, SHAOHONG
LI, HUI
LI, YUN
CHEN, HUIGUO
WU, WEIBING
ZHOU, WEI
WANG, CUIPING
LIAO, HONGYING
GU, LIJIA
Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
title Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
title_full Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
title_fullStr Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
title_full_unstemmed Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
title_short Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
title_sort maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493745/
https://www.ncbi.nlm.nih.gov/pubmed/23226738
http://dx.doi.org/10.3892/etm.2012.690
work_keys_str_mv AT zhangjian maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT zhangweiqing maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT huangshaohong maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT lihui maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT liyun maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT chenhuiguo maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT wuweibing maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT zhouwei maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT wangcuiping maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT liaohongying maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT gulijia maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials